Impressive Semaglutide Outcomes in Obesity and Heart Failure
August 26, 2023 — Scientists who study semaglutide in obesity are producing a steady stream of impressive results. Yesterday in the New England Journal of Medicine, a randomized controlled trial in persons with obesity and heart failure with preserved ejection fraction demonstrated superior weight reduction, improvement in heart failure, better physical functioning, and a halving of serious adverse events. […]
